UroLift
UroLift is a minimally invasive medical device system that uses permanent implants to treat benign prostatic hyperplasia (BPH) without cutting, heating, or removing prostate tissue. It is owned by Teleflex Incorporated (NYSE: TFX) and sold to urologists and hospitals serving men aged 45 and older across 17-plus countries.
- Company typePublic
- Founded2013
- HeadquartersPleasanton, United States
- Headcount5,001–10,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What UroLift does
UroLift is a minimally invasive medical device system developed for the treatment of benign prostatic hyperplasia (BPH), a non-cancerous enlargement of the prostate that obstructs urinary flow in older men. The core technology is a permanent urethral lift implant placed transurethrally via a small delivery device; the implants lift and hold enlarged prostate tissue away from the urethra without cutting, heating, or removing tissue. The next-generation UroLift 2 System with Advanced Tissue Control, introduced in December 2024, is positioned as a unified platform capable of treating all prostate types. The system was originally developed by NeoTract, Inc. (Pleasanton, CA), which received initial FDA clearance in 2013; NeoTract was acquired by Teleflex Incorporated (NYSE: TFX) in October 2017 for up to $1.1 billion and UroLift now operates within Teleflex's Interventional Urology business unit.
The business model is a hardware-based medical device sale of implant-and-delivery kits to urologists, outpatient surgical centers, and hospitals, with the procedure typically performed in-office under local anesthesia. Reimbursement is broadly established, with coverage from Medicare, Medicaid, and major U.S. commercial insurers (Humana, Blue Cross Blue Shield, Kaiser Permanente, Cigna, Anthem), as well as national health systems in Europe and Asia Pacific. The customer base spans men aged 45 and older with BPH symptoms in 17+ countries, with cumulative patient throughput exceeding 200,000 worldwide. Supporting programs include the BPH Advisor patient-education funnel, physician training and credentialing, and the Physician Finder tool. The portfolio is supplemented by the Barrigel Rectal Spacer (hyaluronic acid rectal spacer for prostate radiation therapy), launched in Japan in August 2025.
The company holds FDA 510(k) clearance since 2013, a 2020 expanded indication for prostates up to 100cc, EAU Level 1A classification, AUA Standard of Care recommendation (2018), and NICE Interventional Procedure Guidance in the UK. Endorsements and 5-year clinical data from the L.I.F.T. study underpin a value proposition emphasizing rapid symptom relief, preservation of sexual function, and avoidance of invasive surgery or chronic medication.
UroLift firmographics
Firmographics- Name
- UroLift
- Legal name
- Teleflex Incorporated
- Website
- https://urolift.com
- Company type
- Public
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 5,001–10,000 employees
- Short description
- UroLift is a minimally invasive medical device system that uses permanent implants to treat benign prostatic hyperplasia (BPH) without cutting, heating, or removing prostate tissue. It is owned by Teleflex Incorporated (NYSE: TFX) and sold to urologists and hospitals serving men aged 45 and older across 17-plus countries.
- Ownership category
- akta.pro rank
UroLift industry classification
Industry- Product category
- Urology Medical Devices - BPH Treatment
- SIC
- Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
- akta.pro primary industry
- Endourology & Minimally Invasive Urologic Surgery (HLAKAOAF)
- akta.pro secondary industry
- General Urology (HLAKAOAA)
Keywords
Where UroLift is headquartered
LocationHeadquarters
- HQ city
- Pleasanton
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
UroLift business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Personnel, Marketing or Sales, Technology or R&D, Operations, Infrastructure
Revenue model
- UroLift System Medical Device Sales: The company generates revenue through the sale of UroLift System medical devices and permanent implants to urologists, outpatient surgical centers, and hospitals. The procedure is performed as a one-time outpatient solution with the implants providing durable relief.
- Insurance Reimbursement: The UroLift System is covered by Medicare, national, and commercial insurance plans when medical criteria are met. Major covered insurers include Humana, Blue Cross Blue Shield plans, Kaiser Permanente, Cigna, Anthem, and various Medicare Advantage plans.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | — | Insurance-covered procedure with varying patient out-of-pocket costs |
Go-to-market motion1 record
Distribution channels5 records
Marketing channels8 records
UroLift product offering
Product offeringCore offering
UroLift's core offering is the UroLift System, a minimally invasive medical device that delivers permanent transurethral implants to lift and hold enlarged prostate tissue away from the urethra, treating benign prostatic hyperplasia (BPH) without cutting, heating, or removing prostate tissue. The procedure is performed in urologist offices, outpatient surgical centers, and hospitals, typically under local anesthesia, and is billed via insurance reimbursement. Supporting offerings include the next-generation UroLift 2 System with Advanced Tissue Control and the BPH Advisor patient education program.
Product overview
UroLift, a business unit of Teleflex Interventional Urology, offers the UroLift System as its core product - a minimally invasive permanent implant treatment for benign prostatic hyperplasia (BPH). The portfolio includes the original UroLift System (FDA cleared 2013, expanded indication 2020 for prostates up to 100cc) and the newer UroLift 2 System with Advanced Tissue Control (launched 2024). Supporting the core device is the BPH Advisor patient education program. Additionally, the company offers Barrigel Rectal Spacer, a hyaluronic acid technology for prostate radiation therapy patients, representing a related but distinct product line within the Teleflex interventional urology portfolio.
Differentiator
Problem solved
Functional benefit
Products and services
- UroLift System A minimally invasive permanent implant system for treating benign prostatic hyperplasia (BPH). The system uses tiny implants placed transurethrally to lift and hold excess prostate tissue out of the urethra without cutting, heating, or removing prostate tissue. It is performed in an office setting under local anesthesia and is the only leading BPH procedure shown not to cause sexual dysfunction.
- UroLift 2 System A next-generation UroLift system featuring Advanced Tissue Control technology and a unified platform designed to treat all prostate types, offering enhanced precision and tissue control for physicians performing the BPH procedure.
- BPH Advisor A free patient education program developed with input from board-certified urologists that helps patients obtain a BPH symptom score, learn about treatment options, and share reports with their physicians to enable shared decision-making on enlarged prostate care.
- Barrigel Rectal Spacer A hyaluronic acid-based rectal spacer technology designed to minimize rectal toxicity during prostate radiation therapy, delivering enhanced control and precision for radiation treatment planning and significantly lowering risk of rectal side effects.
Quantifiable outcome
- Over 86% of patients were free from seeking additional procedural treatment for BPH at 4 years
- +5 more outcomes
Companies that use UroLift
Customer profileNamed customers4 records
Segments1 record
Ideal customer profiles1 record
UroLift technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
UroLift partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Teleflex IncorporatedcoreTeleflex Incorporated acquired NeoTract, Inc. in October 2017 in a transaction valued at up to $1.1 billion. NeoTract became a wholly owned subsidiary of Teleflex focused on addressing unmet needs in interventional urology, particularly the UroLift System for BPH treatment.
Scale indicators6 records
Recent moves6 records
Expansion highlights5 records
UroLift competitors and assessment
Company assessmentBroad incumbents
- Karl Storz SE & Co. KG: Karl Storz is a leading endourology and urology visualization/instrumentation manufacturer. Its rigid and flexible endoscopes are used in BPH procedures including TURP and endourological interventions, making it an adjacent incumbent to UroLift's endourological implant approach.
- Cook Medical: Cook Medical manufactures urological devices and surgical implants used in BPH and related urological conditions. As a diversified minimally invasive medical device player, it competes in adjacent urology device categories serving the same urologist customer base.
- Richard Wolf GmbH: Richard Wolf is a German manufacturer of endoscopic and urological surgical instruments, including resectoscopes and laser systems used in BPH surgery. It serves the same endourology customer base and competes for procedure share against UroLift's minimally invasive approach.
- Boston Scientific: Boston Scientific is a large urology and pelvic health incumbent that acquired NxThera (developer of the Rezum steam-based BPH therapy), making it a direct competitor to UroLift in minimally invasive BPH. It also sells a broad portfolio of urological devices and competes broadly with Teleflex Interventional Urology.
- Olympus Corporation: Olympus is a major urology and endourology device manufacturer, offering resectoscopes, laser systems, and TURP equipment used by urologists treating BPH. It competes indirectly by anchoring the traditional surgical BPH workflow that UroLift displaces.
- Lumenis (acquired by Boston Scientific): Lumenis, now part of Boston Scientific, supplies urology laser systems used in BPH procedures such as HoLEP and ThuLEP. These laser enucleation techniques compete with UroLift in the surgical BPH treatment landscape.
Direct peers
- Medi-Tate (acquired by Olympus): Medi-Tate developed the iTind temporarily implanted nitinol device for BPH, acquired by Olympus. It targets the same minimally invasive BPH market and same urologist channel as UroLift with a similar office-based, non-ablative procedural concept.
- PROCEPT BioRobotics: PROCEPT BioRobotics makes the Aquablation system, a robotic minimally invasive BPH treatment. It is the closest direct competitor to UroLift in the office-based, tissue-preserving BPH space, targeting the same urologist customer and BPH patient population.
Emerging players
- SRS Medical Systems: SRS Medical develops urological devices for BPH and related conditions, including the Spanner temporary prostate stent. It is a smaller emerging player in the BPH device space with partial overlap to UroLift's tissue-lifting concept.
Others
- Teleflex Incorporated: Teleflex is the parent company that acquired NeoTract (UroLift's original developer) in 2017 for up to $1.1 billion. UroLift is now a product line within Teleflex's Interventional Urology business unit, so Teleflex is the operating parent rather than a competitor.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
UroLift social profiles
Digital presenceUroLift financial estimates
Financial estimateRevenue estimate
Valuation estimate
UroLift leadership team
Management profileNumber of profiles
Profiles3 records
UroLift subsidiaries and ownership
Company hierarchySubsidiaries1 record
UroLift funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
UroLift M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about UroLift
What does UroLift do?
UroLift's core offering is the UroLift System, a minimally invasive medical device that delivers permanent transurethral implants to lift and hold enlarged prostate tissue away from the urethra, treating benign prostatic hyperplasia (BPH) without cutting, heating, or removing prostate tissue. The procedure is performed in urologist offices, outpatient surgical centers, and hospitals, typically under local anesthesia, and is billed via insurance reimbursement. Supporting offerings include the next-generation UroLift 2 System with Advanced Tissue Control and the BPH Advisor patient education program.
Is UroLift a public or private company?
UroLift is a public company. It is classified as public and is currently operating.
When was UroLift founded?
UroLift was founded in 2013. It employs 5,001 to 10,000 people.
Where is UroLift based?
UroLift is headquartered in Pleasanton, United States, in the North America region.
How does UroLift make money?
Two revenue lines are on record. UroLift System Medical Device Sales are the primary driver. The others are insurance Reimbursement.
Who are UroLift's main competitors?
Broad incumbents on record are Karl Storz SE & Co. KG, Cook Medical, Richard Wolf GmbH, Boston Scientific, Olympus Corporation and Lumenis (acquired by Boston Scientific). Direct peers are Medi-Tate (acquired by Olympus) and PROCEPT BioRobotics. SRS Medical Systems is listed as an emerging player. Teleflex Incorporated is listed as an others.
Does UroLift have an API?
No public API is recorded for UroLift.
What industry is UroLift in?
UroLift's product category is Urology Medical Devices - BPH Treatment. Its primary akta.pro industry code is HLAKAOAF, Endourology & Minimally Invasive Urologic Surgery, with a secondary code of HLAKAOAA, General Urology. Its SIC code is 3842.